3-9-05

Express Mail No. EV 452 774 934 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of:

Bowman et al.

Confirmation No.:

6122

Serial No.:

10/624,098

Art Unit:

3626

Filed:

July 21, 2003

Examiner: To be assigned

For:

PERSONAL HEALTH

Attorney Docket No.:

11389-030-999

COMMUNICATION SYSTEM

CAM No.

902782-999029

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1.

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

Enclosures accompanying this Information Disclosure Statement are: A list of all patents, publications, applications, or other information submitted for 1a. consideration by the office. A legible copy of: 1b.

Each foreign patent; Each publication or that portion which caused it to be listed on the PTO-1449; For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion; all other information or portion which caused it to be listed on the PTO-1449. An English language copy of search report(s) from a counterpart foreign

1c. application or PCT International Search Report.

Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language 1d. abstracts of the non-English language publications.

In accordance with 1276 OG 55, since this application was filed after June 30, 1e. 2003, this Information Disclosure Statement is filed without copies of References, which are U.S. patent documents, U.S. patent applications filed after June 30, 2003 and international applications that have entered the national stage under 35 U.S.C. § 371 after June 30, 2003

2.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):  Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
		Before the mailing of the first Office action on the merits;
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
		(Check either Item 3a or 3b)
	3a.	The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
	3b.	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
		<ul> <li>enclosed</li> <li>to be charged to Jones Day Deposit Account No. 50-3013.</li> </ul>
		(Item 3b to be checked if any reference known for more than 3 months)
4.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
	The Co	ertification Statement in Item 5 below is applicable.
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:  enclosed.
		☐ to be charged to Jones Day Deposit Account No. 50-3013
5.		Certification Statement (applicable if Item 3a or Item 4 is checked)
		(Check either Item 5a or 5b)
	5a.	☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not <b>received</b> by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign

patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

		days prior to the ming or this miorimition discrete concerns.
6.	$\boxtimes$	This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).
		(Check appropriate Items 6a, 6b and/or 6c)
	6a.	A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No. 09/511,963, filed on February 24, 2000, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
	6c.	Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7.	$\boxtimes$	This is a Supplemental Information Disclosure Statement. (Check Item 7a)
	7a.	☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on July 21, 2003.
8.		The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
9.		No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).
Data	Manah	Respectfully submitted,
Date:	waren	For: Ognian V. Shentov 38,051 By: Michael Fainberg 50,441 JONES DAY 222 East 41st Street New York, New York 10017 (212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO. 11389-030-999 CAM 902782-999029 10/624,098

APPLICANT

Bowman et al.

FILING DATE GROUP
July 21, 2003 3626

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,826,696	11/30/2004	Chawla et al.	713	201	
	A02	6,449,598	09/10/2002	Green et al.	705	2	
	A03	6,401,072	06/2002	Haudenschild et al.	705	3	
-	A04	6,385,611	05/07/2002	Cardona, Carlos	707	6	
	A05	6,362,836 B1	03/26/2002	Shaw et al.	345	744	
	A06	6,334,778	01/01/2002	Brown	273	429	
	A07	6,347,374	02/12/2002	Drake et al.	713	200	
	A08	6,2952,796	09/18/2001	Drucker et al.	707	4	
	A09	6,263,330	07/17/2001	Bessette, Luc	707	4	
	A10	6,253,228 B1	06/26/2001	Ferris et al.	709	203	
	A11	6,189,036	02/13/2001	Kao	709	229	
	A12	6,178,416 B1	01/23/2001	Thompson et al.	707	3	
+	A13	6,167,523	12/26/000	Strong	713	201	
	A14	6,141,759	10/31/2000	Braddy	713	201	
	A15	6,112,183	08/29/2000	Swanson et al.	705	2	
	A16	6,092,196	07/18/2000	Reiche	713	200	
	A17	6,073,163	06/6/000	Clark et al.	709	203	
	A18	6,073,106	06/6/2000	Rosen et al.	705	3	
	A19	6,070,160	05//30/2000	Geary	707	4	
	A20	6,031,818	02/29/2000	Lo et al.	370	216	
	A21	6,018,619	01/25/2000	Allard et al.	709	224	
	A22	6,006,269	12/21/1999	Phaal	709	227	
	A23	5,996,715	10/12/1999	Sweeney et al.	707	203	
	A24	5,978,842	11/02/1999	Noble et al.	709	218	
	A25	5,974,412	10/26/1999	Hazlehurst et al.	707	3	
	A26	5,967,789	10/19/1999	Segel et al.	434	236	
	A27	5,960,403	09/28/1999	Brown	705	2	
	A28	5,953,704	09/14/1999	McIlroy et al.	705	2	
	A29	5,915,240	06/22/1999	Karpf	705	2	
	A30	5,905,884	05/18/1999	Williams	709	227	
	A31	5,903,889	0511//1999	De la Huerga et al.	707	3	- <u></u>
	A32	5,867,821	02/02/1999	Ballantyne et al.	705	2	
	A33	5,857,190	01/05/1999	Brown, Matt	707	10	
	A34	1	01/19/1999	Kwang et al.	709	203	

_	A35	5,848,397	12/8/1998	Marsh et al.	705	14
	A36	5,845,255	12/1998	Mayaud	705	3
	A37	5,841,970	11/24/1998	Tabuki	713	201
	A38	5,832,488	11/1998	Eberhardt	707	10
	A39	5,827,180	10/1998	Goodman	600	300
	A40	5,809,476	09-1998	Ryan, John Kevin	705	2
	A41	5,815,665	09/29/1998	Teper et al.	709	229
	A42	5,790,785	08/04/1998	Klug et al.	713	202
	A43	5,772,585	06/1998	Lavin et al.	600	300
	A44	5,664,207	09/1997	Crumpler et al.	715	505
	A45	5,664,109	09/1997	Johnson et al.	705	2
	A46	5,629,981	05/1997	Nerlikar	713	168
	A47	5.588,148	12/24/1996	Landis et al.	707	1
	A48	5,572,422	11/1996	Nematbakhsh et al.	705	3
	A49	5,560,008	09/24/1996	Johnson et al.	713	201
-	A50	5,559,888	09/1996	Jain et al.	380	25
	A51	5,559,885	09/1996	Drexler et al.	235	380
	A52	5,550,971	8/1996	Brunner et al.	395	161
	A53	5,465,082	11/1995	Chaco	340	825.49
	A54	5,327,341	07/1994	Whalen et al.	705	3
	A55	5,325,294	06/1994	Keene	705	3
	A56	5,301,246	04/1994	Archibald et al.	379	142.06
	A57	5,301,105	04/1994	Cummings, Jr.	705	2
	A58	5,241,671	08/1663	Reed et al.	707	104.1
•	A59	5,150,409	09/1992	Elsner	713	177
	A60	5,491,800	02/1996	Goldsmith et al.	709	221
	A61	5,430,875	07/1995	Ma, Yin-Shur D.	719	318
	A62	5,251,152	10/1993	Notess, Peter C.	709	224
	A63	4,984,272	01/1991	McIlroy et al.	713	202
	A64	4,960,982	10/1990	Takahira	235	382
	A65	4,949,251	08/1990	Griffen et al.	714	20
	A66	4,916,611	04/1990	Doyle, Jr. et al.	705	2
	A67	4,882,474	11/1989	Anderl et al.	235	380
	A68	4,858,121	08/1989	Barber et al.	705	2
	A69	4,868,376	09/1989	Lessin et al.	235	492
	A70	4,812,994	03/1989	Taylor et al.	705	410
	A71	4,315,309	02/1982	Coli	705	3

EXAMINER /Kristine Rapillo/ DATE CONSIDERED	10/09/2008
---------------------------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.